Premium
VAB‐6 combination chemotherapy in resected stage II‐B testis cancer
Author(s) -
Vugrin Davor,
Whitmore Willet F.,
Herr Harry W.,
Sogani Pramod,
Golbey Robert B.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830101)51:1<5::aid-cncr2820510103>3.0.co;2-j
Subject(s) - medicine , chemotherapy , stage (stratigraphy) , oncology , cancer , gynecology , paleontology , biology
Twenty‐four patients with resected Stage II‐B nonseminomatous germ cell tumors of the testis received adjuvant chemotherapy with the modified VAB‐6 regimen for one year. Eighteen patients had nodal category N2B and six nodal category N3 (extranodal extension of tumor). Adjuvant VAB‐6 started with two four day inductions at approximately four week intervals. Induction was cyclophosphamide 600 mg/m 2 IV, vinblastine 4 mg/m 2 IV, dactinomycin 1 mg/m 2 IV, bleomycin 30 mg IV on day 1, then bleomycin 20 mg/m 2 /day by continuous 24 hour infusion for three days, and cis‐platinum 120 mg/m 2 IV on day 4. Maintenance was vinblastine 6 mg/m 2 and dactinomycin 1 mg/m 2 every three weeks. Six patients received a third induction but without bleomycin. All 24 patients remain free of disease with a median follow up of 24 months. Myelosuppression was the major toxicity. Four patients received antibiotics for fever during myelosuppression. In one patient, serum creatinine temporarily rose over 2 mg/dl after cis‐platinum. VAB‐6 is effective in the prevention of recurrences in resected Stage II‐B nonseminomatous germ cell tumors. However, the optimal regimen remains to be defined.